David Solit, MD

Publications

251

6 grants

MPI
Developmental Research Program
NCI · 2026–2031 · via NIH RePORTER
P50CA310825-01
MPI
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancer
NCI · 2026–2031 · via NIH RePORTER
R01CA309345-01
PI
The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response
NCI · 2025–2029 · via NIH RePORTER
R01CA296335-02
PI
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma
NCI · 2024–2029 · via NIH RePORTER
R01CA288692-03
MPI
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer
NCI · 2001–2027 · via NIH RePORTER
P50CA092629-25
MPI
Genomics Core
NCI · 2019–2026 · via NIH RePORTER
P01CA228696-05

Completed grants (8)

MPI
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer
NCI · 2018–2025 · via NIH RePORTER
P50CA221745-05S1
MPI
Defining mechanisms of resistance to hormonal therapy in breast cancer
NCI · 2018–2024 · via NIH RePORTER
R01CA234361-05
PI
Project 1: Role of the H3K27 demethylase KDM6A in bladder cancer pathogenesis
NCI · 2018–2024 · via NIH RePORTER
P01CA221757-05
PI
Development of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutations
NCI · 2018–2024 · via NIH RePORTER
R01CA229624-05
PI
Targeting AKT-Mutant Human Cancers
NCI · 2016–2021 · via NIH RePORTER
R01CA207244-05
PI
MSKCC Pilot Center for Precision Disease Modeling
OD · 2015–2021 · via NIH RePORTER
U54OD020355-05
PI
Defining the temporal sequence of PI3K pathway mutations in bladder cancer
NCI · 2014–2018 · via NIH RePORTER
R01CA182587-05
PI
Targeting BRAF and MEK in tumors with BRAF and RAS mutations.
NCI · 2008–2014 · via NIH RePORTER
R01CA127240-05